Since CD36 null humans are common in some areas and they appear to have a normal life expectancy and no obvious increased risk for specific diseases (14), our results highlight the possibility of designing specific CD36 inhibitors against chronic inflammatory metabolic diseases, such as atherosclerosis. Here, CD36 is linked to atherosclerosis.